CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Surgical Retinal Clinical Trial

— NEOVASC-CD160  

Official title:

CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03940664
• Other study ID #: 2018Ao001
• Status: Completed
• Start date: January 2008
• Est. completion date: July 2017

Study information

• Verified date: May 2019
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aims of this study were

• to analyze CD160 expression in both normal and pathological eyes from human adults

• to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Description:

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.

CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: July 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

inclusion criteria :

• Patients with retinal surgery

• Patients who agree to participate to the study

• Major patient

exclusion criteria :

• Patient under law protection

• Minor patient

Related Conditions & MeSH terms

• Surgical Retinal

Intervention

Other:
• immunohistochemistry on Formalin fixed and paraffin embedded blocks

Locations

Country	Name	City	State
France	Chu Reims	France	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

References & Publications (1)

Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C. CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases. Invest Ophthalmol Vis Sci. 2018 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CD160 staining intensity score	Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160.; The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.	Day0
Secondary	CD105 staining intensity score	Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105.; The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.	Day0